Profile image
Story Views

Last Hour:
Last 24 Hours:

Hemophilia B Pipeline Review H2 2016: Stage of Development and Molecule Type Analysis

Friday, November 11, 2016 2:53
% of readers think this story is Fact. Add your two cents.

Latest Hemophilia B Pipeline Review, H2 2016, provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.

Hemophilia B therapeutics industry report provides comprehensive information on the therapeutics under development for Hemophilia B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemophilia B and features dormant and discontinued projects.

Browse more detail information about Hemophilia B market report at:


Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the defective clotting factor.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key players in Hemophilia B – Pipeline Review, H2 2016:

  • Alnylam Pharmaceuticals, Inc.
  • Amarna Therapeutics B.V.
  • Bayer AG
  • Biogen Inc
  • Catalyst Biosciences, Inc.
  • China Biologic Products, Inc.
  • CSL Limited
  • Dimension Therapeutics, Inc.
  • Green Cross Corporation
  • MolMed S.p.A.

And More

Get a PDF Sample of Hemophilia B Market Research Report at:

Drug Profiles of Included in Hemophilia B Therapeutics Development Market Report

  • AMT-060
  • Cell Therapy for Hemophilia B
  • coagulation factor IX (recombinant)
  • concizumab
  • DTX-101

And other drug profiles

Have any query? ask our expert @

Key Topics Covered:
2.Hemophilia B Overview
3.Hemophilia B Therapeutics Development
4.Pipeline Products for Hemophilia B – Overview
5.Pipeline Products for Hemophilia B – Comparative Analysis
6.Hemophilia B – Therapeutics under Development by Companies
7.Hemophilia B – Therapeutics under Investigation by Universities/Institutes
8.Hemophilia B Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Hemophilia B – Products under Development by Companies
13.Hemophilia B – Products under Investigation by Universities/Institutes
14.Hemophilia B – Companies Involved in Therapeutics Development
15.Hemophilia B Drug Profiles
16.Hemophilia B Dormant Projects
17.Hemophilia B Discontinued Products
18.Hemophilia B Featured News & Press Releases
And Continue…

Get Discount on Hemophilia B Market Research Report at:

This research study help to:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hemophilia B
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hemophilia B pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

About Absolute Report:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.


Mr. Ameya Pingaley

Absolute Reports

+1-408 520 9750

Email –

We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.